DDX19B

Across TCGA pan-cancer cohorts, DDX19B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DDX19B data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DDX19B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DDX19B expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where DDX19B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.869	0.207	.008	16	view →
PDAC	DFS	Median	II,III,IV	0.817	0.735	.018	14	view →
LSCC	DFS	Quartile	All	0.951	1.000	.013	9	view →
HNSC	DFS	Tertile	All	0.906	1.000	.016	9	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DDX19B–LUAD (DFS)

Open the LUAD breakdown →